US20220280610A1 - Method for reducing flu-like symptoms associated with intramuscular administration of interferon using a fast titration escalating dosing regimen - Google Patents
Method for reducing flu-like symptoms associated with intramuscular administration of interferon using a fast titration escalating dosing regimen Download PDFInfo
- Publication number
- US20220280610A1 US20220280610A1 US17/827,282 US202217827282A US2022280610A1 US 20220280610 A1 US20220280610 A1 US 20220280610A1 US 202217827282 A US202217827282 A US 202217827282A US 2022280610 A1 US2022280610 A1 US 2022280610A1
- Authority
- US
- United States
- Prior art keywords
- interferon
- dose
- week
- patient
- titration
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000004448 titration Methods 0.000 title claims abstract description 108
- 206010022004 Influenza like illness Diseases 0.000 title claims abstract description 62
- 238000007918 intramuscular administration Methods 0.000 title claims description 34
- 102000014150 Interferons Human genes 0.000 title abstract description 78
- 108010050904 Interferons Proteins 0.000 title abstract description 78
- 229940079322 interferon Drugs 0.000 title abstract description 71
- 238000000034 method Methods 0.000 title abstract description 37
- 201000006417 multiple sclerosis Diseases 0.000 claims abstract description 38
- 108010005716 Interferon beta-1a Proteins 0.000 claims description 41
- 229960004461 interferon beta-1a Drugs 0.000 claims description 22
- 239000003814 drug Substances 0.000 claims description 12
- 230000002265 prevention Effects 0.000 claims description 6
- 208000012266 Needlestick injury Diseases 0.000 claims description 5
- 230000009471 action Effects 0.000 claims description 4
- 239000003085 diluting agent Substances 0.000 claims description 4
- 239000007788 liquid Substances 0.000 claims description 4
- 229940090047 auto-injector Drugs 0.000 claims description 2
- 238000002347 injection Methods 0.000 description 26
- 239000007924 injection Substances 0.000 description 26
- 238000011282 treatment Methods 0.000 description 22
- 108010005714 Interferon beta-1b Proteins 0.000 description 20
- 230000000694 effects Effects 0.000 description 20
- 108090000467 Interferon-beta Proteins 0.000 description 16
- 229940021459 betaseron Drugs 0.000 description 12
- 239000000203 mixture Substances 0.000 description 12
- 230000009467 reduction Effects 0.000 description 12
- 102000003996 Interferon-beta Human genes 0.000 description 11
- 229940003504 avonex Drugs 0.000 description 11
- 229960001388 interferon-beta Drugs 0.000 description 11
- 238000002560 therapeutic procedure Methods 0.000 description 11
- 229940079593 drug Drugs 0.000 description 10
- 108020004414 DNA Proteins 0.000 description 9
- HEFNNWSXXWATRW-UHFFFAOYSA-N Ibuprofen Chemical compound CC(C)CC1=CC=C(C(C)C(O)=O)C=C1 HEFNNWSXXWATRW-UHFFFAOYSA-N 0.000 description 9
- 238000009472 formulation Methods 0.000 description 9
- 229960001680 ibuprofen Drugs 0.000 description 9
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 8
- 208000000112 Myalgia Diseases 0.000 description 7
- 230000001965 increasing effect Effects 0.000 description 7
- 229940047124 interferons Drugs 0.000 description 7
- 108090000623 proteins and genes Proteins 0.000 description 7
- 206010037660 Pyrexia Diseases 0.000 description 6
- 229940038850 rebif Drugs 0.000 description 6
- 208000024891 symptom Diseases 0.000 description 6
- 102000004127 Cytokines Human genes 0.000 description 5
- 108090000695 Cytokines Proteins 0.000 description 5
- 230000008901 benefit Effects 0.000 description 5
- 239000004615 ingredient Substances 0.000 description 5
- 230000000977 initiatory effect Effects 0.000 description 5
- 102000004169 proteins and genes Human genes 0.000 description 5
- 238000007920 subcutaneous administration Methods 0.000 description 5
- 102100026720 Interferon beta Human genes 0.000 description 4
- 230000000202 analgesic effect Effects 0.000 description 4
- 230000008859 change Effects 0.000 description 4
- 230000005713 exacerbation Effects 0.000 description 4
- 206010016256 fatigue Diseases 0.000 description 4
- 229960005489 paracetamol Drugs 0.000 description 4
- 108091033319 polynucleotide Proteins 0.000 description 4
- 102000040430 polynucleotide Human genes 0.000 description 4
- 239000002157 polynucleotide Substances 0.000 description 4
- 230000003442 weekly effect Effects 0.000 description 4
- 108020004705 Codon Proteins 0.000 description 3
- 208000016192 Demyelinating disease Diseases 0.000 description 3
- 206010012305 Demyelination Diseases 0.000 description 3
- 206010019233 Headaches Diseases 0.000 description 3
- 101001054334 Homo sapiens Interferon beta Proteins 0.000 description 3
- 208000008454 Hyperhidrosis Diseases 0.000 description 3
- 102000002227 Interferon Type I Human genes 0.000 description 3
- 108010014726 Interferon Type I Proteins 0.000 description 3
- 108091028043 Nucleic acid sequence Proteins 0.000 description 3
- 108020004511 Recombinant DNA Proteins 0.000 description 3
- 208000007400 Relapsing-Remitting Multiple Sclerosis Diseases 0.000 description 3
- 210000001744 T-lymphocyte Anatomy 0.000 description 3
- 230000002411 adverse Effects 0.000 description 3
- 229940035676 analgesics Drugs 0.000 description 3
- 239000000730 antalgic agent Substances 0.000 description 3
- 210000003169 central nervous system Anatomy 0.000 description 3
- 230000006378 damage Effects 0.000 description 3
- 231100000869 headache Toxicity 0.000 description 3
- 229960003161 interferon beta-1b Drugs 0.000 description 3
- 230000003902 lesion Effects 0.000 description 3
- 206010025482 malaise Diseases 0.000 description 3
- 238000007726 management method Methods 0.000 description 3
- 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 description 3
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 3
- 230000002829 reductive effect Effects 0.000 description 3
- 150000003431 steroids Chemical class 0.000 description 3
- 238000010254 subcutaneous injection Methods 0.000 description 3
- 239000007929 subcutaneous injection Substances 0.000 description 3
- 230000035900 sweating Effects 0.000 description 3
- 241000271566 Aves Species 0.000 description 2
- 102000006992 Interferon-alpha Human genes 0.000 description 2
- 108010047761 Interferon-alpha Proteins 0.000 description 2
- 102000013462 Interleukin-12 Human genes 0.000 description 2
- 108010065805 Interleukin-12 Proteins 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- 239000002260 anti-inflammatory agent Substances 0.000 description 2
- 229940124599 anti-inflammatory drug Drugs 0.000 description 2
- 230000003376 axonal effect Effects 0.000 description 2
- 230000008499 blood brain barrier function Effects 0.000 description 2
- 210000001218 blood-brain barrier Anatomy 0.000 description 2
- 230000034994 death Effects 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 230000002519 immonomodulatory effect Effects 0.000 description 2
- 210000002865 immune cell Anatomy 0.000 description 2
- 230000008595 infiltration Effects 0.000 description 2
- 238000001764 infiltration Methods 0.000 description 2
- 206010022000 influenza Diseases 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 229940117681 interleukin-12 Drugs 0.000 description 2
- 230000000670 limiting effect Effects 0.000 description 2
- 210000002540 macrophage Anatomy 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 210000004248 oligodendroglia Anatomy 0.000 description 2
- 229920001184 polypeptide Polymers 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 102000004196 processed proteins & peptides Human genes 0.000 description 2
- 108090000765 processed proteins & peptides Proteins 0.000 description 2
- 229940043274 prophylactic drug Drugs 0.000 description 2
- 239000012658 prophylactic medication Substances 0.000 description 2
- 201000008628 secondary progressive multiple sclerosis Diseases 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 206010067484 Adverse reaction Diseases 0.000 description 1
- 208000023275 Autoimmune disease Diseases 0.000 description 1
- 210000001266 CD8-positive T-lymphocyte Anatomy 0.000 description 1
- 102000053602 DNA Human genes 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 101000599940 Homo sapiens Interferon gamma Proteins 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 102000006386 Myelin Proteins Human genes 0.000 description 1
- 108010083674 Myelin Proteins Proteins 0.000 description 1
- 208000012902 Nervous system disease Diseases 0.000 description 1
- 241000209094 Oryza Species 0.000 description 1
- 235000007164 Oryza sativa Nutrition 0.000 description 1
- 230000006044 T cell activation Effects 0.000 description 1
- 230000033540 T cell apoptotic process Effects 0.000 description 1
- 230000006052 T cell proliferation Effects 0.000 description 1
- 206010043087 Tachyphylaxis Diseases 0.000 description 1
- 206010054094 Tumour necrosis Diseases 0.000 description 1
- 241000251539 Vertebrata <Metazoa> Species 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 229940086245 acetaminophen 650 mg Drugs 0.000 description 1
- 210000001642 activated microglia Anatomy 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 230000003044 adaptive effect Effects 0.000 description 1
- 230000006838 adverse reaction Effects 0.000 description 1
- 125000003275 alpha amino acid group Chemical group 0.000 description 1
- 125000000539 amino acid group Chemical group 0.000 description 1
- 230000030741 antigen processing and presentation Effects 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 210000001130 astrocyte Anatomy 0.000 description 1
- 210000003719 b-lymphocyte Anatomy 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000036760 body temperature Effects 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 125000000837 carbohydrate group Chemical group 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 210000004978 chinese hamster ovary cell Anatomy 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 208000007118 chronic progressive multiple sclerosis Diseases 0.000 description 1
- 230000007012 clinical effect Effects 0.000 description 1
- 230000019771 cognition Effects 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 238000007405 data analysis Methods 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 230000002939 deleterious effect Effects 0.000 description 1
- 210000004443 dendritic cell Anatomy 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000011979 disease modifying therapy Methods 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 229940077362 extavia Drugs 0.000 description 1
- 238000000855 fermentation Methods 0.000 description 1
- 230000004151 fermentation Effects 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 102000043557 human IFNG Human genes 0.000 description 1
- 229940098416 ibuprofen 400 mg Drugs 0.000 description 1
- 239000000411 inducer Substances 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 208000027866 inflammatory disease Diseases 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 239000011810 insulating material Substances 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 239000012669 liquid formulation Substances 0.000 description 1
- 230000008376 long-term health Effects 0.000 description 1
- 238000011866 long-term treatment Methods 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 210000004962 mammalian cell Anatomy 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 210000000274 microglia Anatomy 0.000 description 1
- 239000003226 mitogen Substances 0.000 description 1
- 238000002703 mutagenesis Methods 0.000 description 1
- 231100000350 mutagenesis Toxicity 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 210000005012 myelin Anatomy 0.000 description 1
- 210000000581 natural killer T-cell Anatomy 0.000 description 1
- 239000005445 natural material Substances 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 230000004770 neurodegeneration Effects 0.000 description 1
- 230000000926 neurological effect Effects 0.000 description 1
- 231100000957 no side effect Toxicity 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- 125000003729 nucleotide group Chemical group 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 239000013612 plasmid Substances 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000000770 proinflammatory effect Effects 0.000 description 1
- 230000002062 proliferating effect Effects 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- 238000010188 recombinant method Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 235000009566 rice Nutrition 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 230000001953 sensory effect Effects 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 210000005070 sphincter Anatomy 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 210000004281 subthalamic nucleus Anatomy 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 238000011287 therapeutic dose Methods 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 210000004885 white matter Anatomy 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/21—Interferons [IFN]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/21—Interferons [IFN]
- A61K38/215—IFN-beta
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/555—Interferons [IFN]
- C07K14/565—IFN-beta
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Definitions
- the present invention relates generally to a method for treating multiple sclerosis (MS), and for reducing flu-like symptoms generally associated with administration of interferons.
- the method uses a fast-titration escalating dosing regimen of intramuscularly administered interferon.
- the invention also relates to titration packaging to promote compliance with the dosage titration.
- MS Multiple sclerosis
- MS has an unknown etiology
- T helper 1 (TH1)-cell mediated autoimmune disease Development of lesions is characterized by accumulation of activated microglia and macrophages. Acute plaques are characterized by blood brain barrier damage, infiltration by activated CD4+ T cells and clonotypic CD8+ T cells that recognize CNS autoantigens, and the presence of reactive astrocytes and proliferating oligodendrocytes. Pro-inflammatory cytokines, e.g. interleukin 12 (IL-12) and tumour-necrosis factor-a (TNF-a), are also present.
- IL-12 interleukin 12
- TNF-a tumour-necrosis factor-a
- Relapse-remitting MS the most common form of the disease, is characterized by multiple exacerbations over time. Exacerbations are attacks on vision, motor, sensory, and sphincter control and cognitive processes. Patients with relapse-remitting MS do not completely recover from these exacerbations and accrue neurologic disability with each subsequent exacerbation.
- IFN- ⁇ Natural human fibroblast interferon-beta
- IFN- ⁇ has immunomodulatory effects, which include modulating cytokine levels (e.g., inducing Th1 (T-helper 1) related cytokines and Th2 related cytokines), inhibiting T-cell activation and proliferation, inhibiting transmigration of autoreactive T cells into the CNS, increasing T cell apoptosis, and reducing expression of molecules required for antigen presentation.
- T-helper 1 Th1 related cytokines
- Th2 Th2 related cytokines
- IFN- ⁇ has well-established clinical effects and studies evidence that IFN- ⁇ works against multiple sclerosis through immunomodulation.
- IFN- ⁇ 1a interferon beta-1 ⁇
- IFN- ⁇ 1b interferon beta-1b
- IFN- ⁇ 1a and IFN- ⁇ 1b are two distinct molecules with different recommended dosages, routes of administration and dosing intervals.
- IFN- ⁇ 1a is a 166 amino acid glycoprotein with a predicted molecular weight of approximately 22,500 daltons. It is produced by recombinant DNA technology using genetically engineered Chinese Hamster Ovary cells into which the human interferon beta gene has been introduced. The amino acid sequence is identical to that of natural human interferon beta.
- IFN- ⁇ 1b has 165 amino acids and an approximate molecular weight of 18,500 daltons. It does not include the carbohydrate side chains found in the natural material. IFN- ⁇ 1b is manufactured by bacterial fermentation of a strain of Escherichia coli that bears a genetically engineered plasmid containing the gene for human interferon beta ser17 . The specific activity of IFN- ⁇ 1a and IFN- ⁇ 1b are different and based on different World Health Organization (WHO) reference standards of recombinant interferon beta and different assays used to measure activity.
- WHO World Health Organization
- Current IFN- ⁇ 1a treatments include Avonex®, CinnoVexTM, Rebif®, and Resigene.
- Current IFN- ⁇ 1b treatments include Betaseron® in the US and Betaferon® in Europe, and Extavia®.
- Avonex® and CinnoVexTM are administered intramuscularly, while the other interferon treatments for MS are administered subcutaneously.
- IFN- ⁇ 1a and IFN- ⁇ 1b share similar side effect profiles.
- a common adverse event associated with interferon therapies are flu-like symptoms that develop within a few hours after administration and subside within 24 hours. Flu-like symptoms associated with administration of interferons include fever, muscle aches (myalgia), chills, sweating, fatigue, headache, and malaise. The exact mechanism for the development of flu-like symptoms is not well understood but occurs among patients taking interferons irrespective of disease state. It has been postulated that interferons stimulate the sub-thalamic nucleus, thus affecting temperature, as well as local cytokines resulting in other symptoms.
- Betaseron® (10/07) label includes titration instructions for subcutaneous administration of IFN- ⁇ 1b over a six-week period, with full dose beginning in week 7:
- the Betaseron® label indicates dose titration may reduce flu-like symptoms.
- the European Betaferon® label (1-8-24) includes titration instructions for subcutaneous administration over a three week period, with full dose beginning in week 4:
- Week 1 1 ⁇ 4 of a dose (0.0625 mg/0.25 ml)
- Week 2 1 ⁇ 2 of a dose (0.125 mg/0.5 ml)
- Week 3 3 ⁇ 4 of a dose (0.1875 mg/0.75 ml)
- the European Betaferon® label has a three week titration period with 1 ⁇ 4 dose increments
- the label recommends dose titration at the start of treatment in order to increase tolerability and to reduce side effects, only generally, at the start of therapy.
- the 3 week titration period of the European Betaferon® label is silent with respect to treating flu-like symptoms.
- Two clinical studies reveal that 1 ⁇ 4 dose increments over a three-week period do not provide a significant reduction in flu-like symptoms in comparison to slow titration regimens.
- Group A received 8 million IU (MIU) of Betaseron® every second day (the standard dose) during weeks 0-4.
- Groups B and C each received Betaseron® according to the titration schedule starting at 2 MIU (25% of the standard dose) and increased at increments of 2 MIU (25% of the standard dose) during weeks 0-4.
- Bayas et al. described dose titration for administration of IFN- ⁇ 1b (which is only administered subcutaneously) where treatment began at 20 to 25% dose for 1 week, increased to 50% dose the second week, and if treatment was tolerated, increased to full dose.
- interferon- ⁇ dosage should be reduced or kept at the same level for a longer time until improved drug tolerability allows an increase.
- Wroe (Wroe S J. Effects of dose titration on tolerability and efficacy of interferon beta-1b in people with multiple sclerosis. J Int Med Res 33:309-18, 2005) evaluated whether a slower, four-stage, 4 week titration to a final dose of 250 ⁇ g subcutaneous IFN- ⁇ 1b might improve tolerability over a more rapid two-stage, 2 week titration in patients with relapsing-remitting MS over a 3-month period.
- IFN- ⁇ 1b was subcutaneously administered, initially at 62.5 ⁇ g (1 ⁇ 4 dose) every other day for 9 days, and then at 1 ⁇ 4 dose increments (125 ⁇ g and 187.5 ⁇ g, respectively) on days 11 and 21, and a full dose (250 ⁇ g) beginning on day 31 (i.e. in the middle of week 5) for the remainder of the 3-month treatment. See FIG. 1 of Wroe et al.
- IFN- ⁇ 1b was subcutaneously administered, initially at 125 ⁇ g (1 ⁇ 2 dose) every other day for 2 weeks and then at full dose for the remainder of the 3-month treatment.
- One of the primary adverse events assessed was flu-like symptoms.
- Wroe reported no noticeable differences with respect to the occurrence of adverse events between the two treatment groups, e.g., the incidence rates of flu-like symptoms were similar in the slow—(32.4%) and rapid titration (41.9%) groups (FIG. 3 of Wroe et al). Wroe concluded that a rapid-titration regimen (1 ⁇ 2 dose increments, with a full dose beginning in week 3) results in a quicker onset of clinical benefit and slow titration (1 ⁇ 4 dose increments, with a full dose beginning in the middle of week 5) showed a non-significant reduction in flu-like symptoms compared to the rapid-titration regimen.
- the Rebif® label includes titration instructions for subcutaneous administration of IFN- ⁇ 1a three times per week over a 4-week period, with full dose administered in week 5:
- Week 3-4 1 ⁇ 2 of a dose—subcutaneous injection 3 ⁇ /week
- the European Rebif® label recommends a gradual increase during a 4 week period to reduce adverse reactions.
- the 1 ⁇ 5 dose during the first two weeks serves the purpose of allowing tachyphylaxis to develop, thus reducing side effects.
- Both the US and European labels are silent with respect to treating flu-like symptoms associated with administration of interferon-beta. All of the products and clinical studies discussed thus far relate to subcutaneous administration of IFN- ⁇ 1a or IFN- ⁇ 1b .
- the Brandes et al. study was a multi-site, randomized, open-label, 12-week study.
- Group 1 patients received (IM) IFN- ⁇ 1a at a dose of 30 ⁇ g once weekly with no titration.
- Groups 2 and 3 received (IM) IFN- ⁇ 1a at 1 ⁇ 4 dose during weeks 1 and 2, 1 ⁇ 2 dose for weeks 3 and 4, 3 ⁇ 4 dose at weeks 5 and 6, and a full dose (30 ⁇ g) for weeks 7-12.
- Groups 1 and 2 received acetaminophen 650 mg 1 hour before each (IM) IFN- ⁇ 1a injection, then every 4 hours as needed.
- Group 3 received ibuprofen 400 mg 1 hour before each (IM) IFN- ⁇ 1a injection, again at 6 hours following injection, then every 6 hours as needed. Flu-like symptoms were recorded at three time points: baseline (first dose of analgesic, 1 hour pre-injection); Time A (second dose of analgesic, 4 hours post-injection); and Time B (12-15 hours post-injection).
- Frohman et al (Frohman E et al. Disease-Modifying Therapy in Multiple Sclerosis: Strategies for Optimizing Management. Neurologist 8:227-236, 2002) in a comprehensive review of MS therapy management, recommends initiating treatment during the tapering phase of a steroid regimen and applying a fractionated dosing scheme in patients treated with either Avonex®, Rebif® or Betaseron® in combination with a nonsteroidal anti-inflammatory agent. In particular, patients were started at 25% of the recommended dose and dosages were increased by 25% increments weekly to every other week. Frohman et al. describes the 25% dose as “a dose usually associated with minimal to no side effects” given that interferon-related side effects are dose-response related.
- Frohman et al. states, “If patients experience severe and limiting side effects as the dose is increased, we will generally prolong titration, escalating by the same increment every 2 to 4 weeks. With this approach, we have had very few patients fail drug initiation.” Thus, Frohman teaches to err on the side of an extended titration schedule.
- the inventors have surprisingly found that by decreasing the time period of the dose titration schedule for the intramuscular administration of interferon (“fast titration”), the appearance of flu-like symptoms is significantly reduced as compared to a longer dose titration schedule (“slow titration”).
- the present invention provides a method for treating multiple sclerosis, which includes intramuscularly administering an interferon to a patient once per week, and specifically includes an initial titration period wherein the interferon is administered in an escalating dose regimen (a “titration period”).
- the titration period includes a one-quarter dose in week one, a one-half dose in week two, a three-quarter dose in week 3, and a full therapeutically effective dose in week 4 and thereafter.
- the present invention also provides a method for reducing flu-like symptoms associated with the administration of an interferon to a patient with multiple sclerosis, including (a) intramuscularly administering the interferon to the patient according to an escalating dosing regimen in weeks 1 to 3; and (b) intramuscularly administering a full therapeutically effective dose of interferon in week 4.
- the invention also relates to a titration package for enabling compliance with these methods, wherein the dosage of interferon changes over a period of time.
- the titration package includes interferon delivery devices containing an interferon, and instructions for the patient to administer the interferon in an escalating dose regimen during a titration period.
- FIG. 1 is a flow chart showing the design of a “fast vs. slow” titration trial. Note that in the Example below, additional subjects were investigated.
- FIG. 2 is a table with the titration schedules in a clinical study.
- Patients in Treatment Group 1 received a full intramuscular dose of Avonex® each week for 8 weeks.
- Patients in Treatment Group 2 received intramuscular doses of Avonex® according to a fast titration schedule (1 ⁇ 4 dose in week 1, 1 ⁇ 2 dose in week 2, 3 ⁇ 4 dose in week 3, and full dose in weeks 4-8).
- Patients in Treatment Group 3 received intramuscular doses of Avonex® according to a slow titration schedule (1 ⁇ 4 dose in weeks 1-2, 1 ⁇ 2 dose in weeks 3-4, 3 ⁇ 4 dose in weeks 5-6, and full dose in weeks 7-8). All patient groups received prophylactic medication.
- FIG. 3 describes a method of scoring flu-like symptoms (FLS) in accordance with the invention.
- FIG. 4 is a line graph of the primary outcome variable and shows the change in total flu-like symptom (FLS) score from pre-injection to 4 to 6 hours after injection over 8 weeks.
- FLS total flu-like symptom
- FIG. 5 is a line graph of the secondary outcomes variable and shows the change in total flu-like symptom (FLS) score from pre-injection to 12 to 15 hours after injection over 8 weeks.
- FLS total flu-like symptom
- FIG. 6 is a table of the secondary outcome variable and provides the odds ratio of incidence of flu-like symptom (FLS) score at 4 to 6 hours and at 12 to 15 hours after injection over 8 weeks.
- FLS flu-like symptom
- FIG. 7 provides data comparing the effect on flu-like symptoms of no titration, fast titration and slow titration.
- FIG. 8 is a bar graph comparing the change in flu-like symptoms (FLS) at 4-6 hours, comparing no titration to fast titration.
- FIG. 9 provides data comparing the effect on flu-like symptoms of no titration to slow titration.
- the invention provides a method for treating a subject with multiple sclerosis, by intramuscularly administering an interferon using an initial escalating dosage regimen or titration period. Treatment is preferably once a week.
- the escalating dosage regimen typically involves administration of a one-quarter dose in week one, a one-half dose in week two, a three-quarter dose in week 3, and a full therapeutically effective dose in week 4 and thereafter.
- the week one dose is about 7.5 micrograms
- the week two dose is about 15 micrograms
- the week three dose is about 22.5 micrograms
- the week four dose is about 30 micrograms.
- the interferon is interferon ⁇ . In a more preferred embodiment, the interferon is an interferon ⁇ 1 . In a most preferred embodiment, the interferon is interferon ⁇ 1a .
- the invention also provides a method for reducing the flu-like symptoms which can accompany the intramuscular administration of an interferon.
- the invention provides a method involving the intramuscularly administration of interferon to the patient according to an escalating dosing regimen in weeks 1 to 3; and then the administration of a full therapeutically effective dose of interferon in week 4.
- Reducing flu-like symptoms can be measured in reduction of severity of symptoms, and/or reduction in incidence of flu-like symptoms.
- the reduction can be measured at various timepoints post-injection, for example 4 to 6 hours post-injection and 12 to 15 hours post-injection.
- the reduction in severity of flu-like symptoms at 4 to 6 hours is at least 40%, more preferably at least 50%, even more preferably at least 60%, and most preferably at least 70%.
- the reduction in severity of flu-like symptoms at 12 to 15 hours is preferably at least 10%, more preferably at least 20%, even more preferably at least 25%, and most preferably at least 30%.
- the reduction in incidence of flu-like symptoms at 4 to 6 hours is preferably at least 5%, more preferably at least 10%, even more preferably at least 15%, and most preferably about 20%.
- the reduction in incidence of flu-like symptoms at 12 to 15 hours is at least 10%, more preferably at least 15%, even more preferably at least 20%, and most preferably about 25%.
- the invention includes administering one quarter of the therapeutically effective dose in week 1, half of the therapeutically effective dose in week 2, and three-quarters of the full therapeutically effective dose in week 3.
- the full therapeutically effective dose is 30 micrograms.
- Flu-like symptoms can include, for example, fever, muscle aches (myalgia), chills, sweating, fatigue, headache, and malaise, and can be scored in accordance with the method of FIG. 3 .
- the methods of the invention can further include the administration of an analgesic or anti-inflammatory drug, or a mixture thereof.
- the drug may be a steroid or a non-steroidal anti-inflammatory drug.
- Preferred drugs include acetaminophen and ibuprofen.
- the invention also provides titration packages, wherein the interferon is presented in a way to promote compliance with the escalating dosage regimen, and ultimately the long-term treatment using the interferon.
- the package includes interferon and delivery devices for the interferon.
- the interferon may be in lyophilized form, and thus packaged in a jar or vial.
- the package also preferably contains a device, such as a syringe, which is pre-filled with a diluent for lyophilized interferon.
- the interferon may in liquid form.
- the interferon may be provided in pre-filled syringes.
- the syringes may be provided with the exact dosage for weeks 1-4 and thereafter.
- an accessory to the delivery device may also be provided, which when used in combination with the syringe, is capable of titrating the correct volume or dosage for the particular week of the escalating dosage regimen (titration period).
- the syringe may also be provided with a needle stick prevention device.
- a prevention device can include a needle shield, which may be automated.
- the shield may be completely automatic (i.e., without any action by the patient), or may be activated by the patient.
- the interferon may also be provided in other delivery devices, such as a pen.
- the titration package also preferably contains instructions for intramuscular administration of the interferon by a patient during a titration period, wherein the interferon is preferably administered at a one-quarter dose in week one, a one-half dose in week two, a three-quarter dose in week 3, and a full therapeutically effective dose in week 4.
- Interferon is a small, species-specific, single chain polypeptide, produced by mammalian cells in response to exposure to a variety of inducers such as viruses, polypeptides, mitogens and the like.
- the most preferred interferon used in the invention is glycosylated, human, interferon- ⁇ that is glycosylated at residue 80 (Asn 80) and that is preferably derived via recombinant DNA technologies. This preferred glycosylated interferon- ⁇ is called “interferon- ⁇ 1a ”.
- the term “interferon- ⁇ 1a ” is also intended to encompass all mutant forms (i.e., Example 1) provided that the mutants are also glycosylated at the Asn 80 residue.
- Preferred interferon- ⁇ 1a polynucleotides that may be used in the present methods of the invention are derived from the wild-type interferon ⁇ gene sequences of various vertebrates, preferably mammals and are obtained using methods that are well-known to those having ordinary skill in the art such as the methods described in the following U.S. patents: U.S. Pat. No. 5,641,656 (issued Jun. 24, 1997: DNA encoding avian type I interferon proprotein and mature avian type I interferon), U.S. Pat. No. 5,605,688 (Feb. 25, 1997-recombinant dog and horse type I interferons); U.S. Pat. No. 5,231,176 (Jul.
- Mutants of interferon- ⁇ 1a may be used in accordance with this invention. Mutations are developed using conventional methods of directed mutagenesis, known to those of ordinary skill in the art. Moreover, the invention provides for functionally equivalent interferon- ⁇ 1a polynucleotides that encode for functionally equivalent interferon-beta-1a polypeptides.
- the term “interferon” includes, but is not limited to, the agents listed above as well as their functional equivalents.
- the term “functional equivalent” therefore refers to an interferon- ⁇ 1a protein or a polynucleotide encoding the interferon-beta-1a protein that has the same or an improved beneficial effect on the mammalian recipient as the interferon of which it is deemed a functional equivalent.
- a functionally equivalent protein can be produced by recombinant techniques, e.g., by expressing a “functionally equivalent DNA”.
- the instant invention embraces interferon- ⁇ 1a proteins encoded by naturally-occurring DNAs, as well as by non-naturally-occurring DNAs which encode the same protein as encoded by the naturally-occurring DNA. Due to the degeneracy of the nucleotide coding sequences, other polynucleotides may be used to encode interferon- ⁇ 1a . These include all, or portions of the above sequences which are altered by the substitution of different codons that encode the same amino acid residue within the sequence, thus producing a silent change. Such altered sequences are regarded as equivalents of these sequences.
- Trp (F) is coded for by two codons, TTC or TTT
- Tyr (Y) is coded for by TAC or TAT
- His (H) is coded for by CAC or CAT.
- Trp (W) is coded for by a single codon, TGG.
- the interferon may be administered per se as well as in the form of pharmaceutically acceptable esters, salts, and other physiologically functional derivatives thereof.
- the interferon preferably is utilized together with one or more pharmaceutically acceptable carrier(s) and optionally any other therapeutic ingredients.
- the carrier(s) must be pharmaceutically acceptable in the sense of being compatible with the other ingredients of the formulation and not unduly deleterious to the recipient thereof.
- the interferon is provided in an amount effective to achieve the desired pharmacological effect, as described above, and in a quantity appropriate to achieve the desired daily dose.
- the formulations include those suitable for intramuscular administration.
- the formulations may conveniently be presented in unit dosage forms and may be prepared by any of the methods well known in the art of pharmacy. Such methods generally include the step of bringing the active ingredient(s) into association with a carrier which constitutes one or more accessory ingredients. Typically, the formulations are prepared by uniformly and intimately bringing the active ingredient(s) into association with a liquid carrier.
- the formulations may be presented in unit-dose or multi-dose form.
- the formulations may further include one or more accessory ingredient(s) selected from diluents, buffers, disintegrants, surface active agents, thickeners, lubricants, preservatives (including antioxidants), and the like.
- a method for treating multiple sclerosis including intramuscularly administering an interferon to a patient once per week, wherein treatment begins with a titration period wherein the interferon is administered at a one-quarter dose in week one, a one-half dose in week two, a three-quarter dose in week 3, and a full therapeutically effective dose in week 4 and thereafter.
- a method for reducing flu-like symptoms associated with administration of an interferon to a patient with multiple sclerosis including:
- escalating dosing regimen comprises administering one quarter of the therapeutically effective dose in week 1, half of the therapeutically effective dose in week 2, and three-quarters of the therapeutically effective dose in week 3.
- a titration package for enabling compliance with a regimen of changing dosage of an interferon over a period of time, the package including interferon delivery devices containing an interferon and instructions for administration by a patient during a titration period, wherein the interferon is administered at a one-quarter dose in week one, a one-half dose in week two, a three-quarter dose in week 3, and a full therapeutically effective dose in week 4.
- the titration package of item 11 further comprising a vial adapter and a syringe pre-filled with a diluent for said lyophilized interferon.
- compositions and processes of the present invention will be better understood in connection with the following examples, which are intended as an illustration only and not limiting of the scope of the invention.
- Various changes and modifications to the disclosed embodiments will be apparent to those skilled in the art and such changes and modifications including, without limitation, those relating to the processes, formulations and/or methods of the invention may be made without departing from the spirit of the invention and the scope of the appended claims.
- Avonex® was studied in a randomized, three-arm, dose-blinded, parallel-group study to determine the effect of Avonex® dose titration, administered intramuscularly, on the severity and incidence of IFN- ⁇ 1a -related flu-like symptoms in healthy volunteers.
- the approved therapeutic dose of Avonex® is 30 ⁇ g weekly by IM administration.
- Group 1 no titration (weekly IM IFN- ⁇ 1a 30 ⁇ g for 8 weeks); Group 2—fast dose titration (quarter-dose increments every week up to 30 ⁇ g over 3 weeks, full dose to Week 8); and Group 3—slow dose titration (quarter-dose increments every 2 weeks up to 30 ⁇ g over 6 weeks, full dose to Week 8). See FIG. 1 .
- FLS flu-like symptoms
- the total score (sum of the 3 symptom scores and fever score) for each of the 3 timepoints (pre-injection, 4 to 6 hours, and 12 to 15 hours) was be calculated during data analysis. For each timepoint, the maximum total score was 12 and the minimum total score was 0. A total score of 2 points or greater above the pre-injection score was considered positive for the presence of FLS.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Zoology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Neurosurgery (AREA)
- General Chemical & Material Sciences (AREA)
- Neurology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biomedical Technology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Toxicology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Dermatology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Infusion, Injection, And Reservoir Apparatuses (AREA)
- Medicinal Preparation (AREA)
Abstract
A combination and method for treating multiple sclerosis (MS), and for reducing flu-like symptoms associated with administration of an interferon to a patient with MS. The method involves intramuscularly administering the interferon to the MS patient according to an escalating dosing regimen in weeks 1 to 3, and a full therapeutically effective dose of interferon in week 4. In one embodiment of the invention, the escalating dosing regimen comprises administering one quarter of the therapeutically effective dose in week 1, half of the therapeutically effective dose in week 2, and three-quarters of the therapeutically effective dose in week 3. Also provided are titration packages for enabling compliance with a regimen of changing dosage of an interferon over a period of time.
Description
- This application is a continuation of U.S. patent application Ser. No. 16/660,038, filed Oct. 22, 2019, which is a continuation of U.S. patent application Ser. No. 15/695,587, filed Sep. 5, 2017, now U.S. Pat. No. 10,500,254, issued on Dec. 10, 2019, which is a continuation of U.S. patent application Ser. No. 14/936,228, filed Nov. 9, 2015, now abandoned, which in turn is a division of U.S. patent application Ser. No. 13/421,197, filed Mar. 15, 2012, now U.S. Pat. No. 9,198,955, issued on Dec. 1, 2015, which in turn claims priority benefit of U.S. provisional patent application Ser. No. 61/476,930, filed Apr. 19, 2011, and 61/452,807, filed Mar. 15, 2011. The disclosure of each application and patent is incorporated herein in its entirety by reference.
- The present invention relates generally to a method for treating multiple sclerosis (MS), and for reducing flu-like symptoms generally associated with administration of interferons. In particular, the method uses a fast-titration escalating dosing regimen of intramuscularly administered interferon. The invention also relates to titration packaging to promote compliance with the dosage titration.
- Multiple sclerosis (MS) is a chronic neurological and inflammatory disorder of the central nervous system, marked by focal autoreactive T-cell and macrophage infiltration through the blood brain barrier that lead to demyelination, and axonal and neuronal loss. In people affected by MS, patches of damage called plaques or lesions appear in seemingly random areas of the CNS white matter. At the site of a lesion, a nerve insulating material, myelin, is lost in demyelination. Inflammation, demyelination, oligodendrocyte death, membrane damage and axonal death all contribute to the symptoms of MS.
- Although MS has an unknown etiology, the classical hypothesis is that MS is a T helper 1 (TH1)-cell mediated autoimmune disease. Development of lesions is characterized by accumulation of activated microglia and macrophages. Acute plaques are characterized by blood brain barrier damage, infiltration by activated CD4+ T cells and clonotypic CD8+ T cells that recognize CNS autoantigens, and the presence of reactive astrocytes and proliferating oligodendrocytes. Pro-inflammatory cytokines, e.g. interleukin 12 (IL-12) and tumour-necrosis factor-a (TNF-a), are also present. There is further evidence that other adaptive immune cells (e.g. TH17 cells and peripheral B lymphocytes) and innate immune cells (dendritic cells, natural killer T cells and resident microglia) play a role in MS pathogenesis.
- Relapse-remitting MS, the most common form of the disease, is characterized by multiple exacerbations over time. Exacerbations are attacks on vision, motor, sensory, and sphincter control and cognitive processes. Patients with relapse-remitting MS do not completely recover from these exacerbations and accrue neurologic disability with each subsequent exacerbation.
- Natural human fibroblast interferon-beta (IFN-β) was the first drug to treat relapse-remitting MS. IFN-β has immunomodulatory effects, which include modulating cytokine levels (e.g., inducing Th1 (T-helper 1) related cytokines and Th2 related cytokines), inhibiting T-cell activation and proliferation, inhibiting transmigration of autoreactive T cells into the CNS, increasing T cell apoptosis, and reducing expression of molecules required for antigen presentation. IFN-β has well-established clinical effects and studies evidence that IFN-β works against multiple sclerosis through immunomodulation.
- There are currently two different recombinant interferon-beta treatments for MS: interferon beta-1α (IFN-β1a) and interferon beta-1b (IFN-β1b). IFN-β1a and IFN-β1b are two distinct molecules with different recommended dosages, routes of administration and dosing intervals. IFN-β1a is a 166 amino acid glycoprotein with a predicted molecular weight of approximately 22,500 daltons. It is produced by recombinant DNA technology using genetically engineered Chinese Hamster Ovary cells into which the human interferon beta gene has been introduced. The amino acid sequence is identical to that of natural human interferon beta. IFN-β1b has 165 amino acids and an approximate molecular weight of 18,500 daltons. It does not include the carbohydrate side chains found in the natural material. IFN-β1b is manufactured by bacterial fermentation of a strain of Escherichia coli that bears a genetically engineered plasmid containing the gene for human interferon betaser17. The specific activity of IFN-β1a and IFN-β1b are different and based on different World Health Organization (WHO) reference standards of recombinant interferon beta and different assays used to measure activity.
- Current IFN-β1a treatments include Avonex®, CinnoVex™, Rebif®, and Resigene. Current IFN-β1b treatments include Betaseron® in the US and Betaferon® in Europe, and Extavia®. Avonex® and CinnoVex™ are administered intramuscularly, while the other interferon treatments for MS are administered subcutaneously.
- Although there is a difference in specific activity between the two types of interferons, IFN-β1a and IFN-β1b share similar side effect profiles. For example, a common adverse event associated with interferon therapies are flu-like symptoms that develop within a few hours after administration and subside within 24 hours. Flu-like symptoms associated with administration of interferons include fever, muscle aches (myalgia), chills, sweating, fatigue, headache, and malaise. The exact mechanism for the development of flu-like symptoms is not well understood but occurs among patients taking interferons irrespective of disease state. It has been postulated that interferons stimulate the sub-thalamic nucleus, thus affecting temperature, as well as local cytokines resulting in other symptoms.
- Generally, the flu-like symptoms will significantly decrease after 2-3 months. However, flu-like symptoms associated with interferon administration at the beginning of treatment can be a significant barrier to the initiation or maintenance of MS therapy, even before the onset of any therapeutic benefit. Use of an escalating dosing regimen (also known as dose titration) has become a routine practice for the administration of interferon therapies to manage side effects at the initiation of therapy. The goal of dose titration is to improve the acceptance and adherence of therapy and, thus, impact long-term health benefits for patients with multiple sclerosis. Currently, there are only two interferon-beta products, Betaseron® and Rebif®, that provide dose titration instructions in their labels. Both Betaseron® and Rebif® are administered subcutaneously.
- The Betaseron® (10/07) label includes titration instructions for subcutaneous administration of IFN-β1b over a six-week period, with full dose beginning in week 7:
- Weeks 1-2—¼ of a dose (0.0625 mg/0.25 ml)
- Weeks 3-4—½ of a dose (0.125 mg/0.5 ml)
- Weeks 5-6—¾ of a dose (0.1875 mg/0.75 ml)
-
Week 7— full dose (0.25 mg/1 ml) - The Betaseron® label indicates dose titration may reduce flu-like symptoms. The European Betaferon® label (1-8-24) includes titration instructions for subcutaneous administration over a three week period, with full dose beginning in week 4:
-
Week 1—¼ of a dose (0.0625 mg/0.25 ml) -
Week 2—½ of a dose (0.125 mg/0.5 ml) -
Week 3—¾ of a dose (0.1875 mg/0.75 ml) -
Week 4—full dose (0.25 mg/1 ml) - Although the European Betaferon® label has a three week titration period with ¼ dose increments, the label recommends dose titration at the start of treatment in order to increase tolerability and to reduce side effects, only generally, at the start of therapy. Unlike the US Betaseron® label which indicates a 6 week titration period and the possibility of a reduction in flu-like symptoms, the 3 week titration period of the European Betaferon® label is silent with respect to treating flu-like symptoms. Two clinical studies reveal that ¼ dose increments over a three-week period do not provide a significant reduction in flu-like symptoms in comparison to slow titration regimens.
- Rice et al (Rice G P A, Ebers G C, Lublin F D, Knobler R L. Ibuprofen Treatment versus Gradual Introduction of Interferon beta-1b in Patients with MS. Neurology 52:1893-1895, 1999) evaluated the effectiveness of dose titration in combination with ibuprofen in reducing the flu-like side effects of Betaseron® administered subcutaneously in 49 patients with Relapsing-Remitting and Secondary Progressive Multiple Sclerosis (RR and SPMS). This was a randomized, open-label, study that compared patients who did not titrate Betaseron® but took ibuprofen prophylaxis (Group A), to those who titrated Betaseron® with (Group B) and without Ibuprofen treatment (Group C). Group A received 8 million IU (MIU) of Betaseron® every second day (the standard dose) during weeks 0-4. Groups B and C each received Betaseron® according to the titration schedule starting at 2 MIU (25% of the standard dose) and increased at increments of 2 MIU (25% of the standard dose) during weeks 0-4. During weeks 0-4, 11% (2 out of 18) of Group A patients developed flu-like symptoms, 6% (1 out of 6) of Group B patients developed flu-like symptoms, and 40% of Group C patients developed flu-like symptoms (Table 1 of Rice et al.). The differences in incidence of flu-like symptoms between the group receiving ibuprofen treatment alone (Group A) and the group receiving dosage escalation and ibuprofen treatment (Group B) does not appear to be significant.
- Moreover, Rice et al. reported that 5 (three from Group A, one from Group B, and one from Group C) of the 49 patients (10%) in the study experienced difficulty while escalating the dose of IFN-β1b, and these patients required either dosage reduction or a delay in the escalating schedule.
- This was common practice according to Bayas et al. (Bayas A and Rieckmann P. Managing the Adverse Effects of Interferon-β Therapy in Multiple Sclerosis. Drug Safety 22(2):149-159, 2000). Bayas et al. described dose titration for administration of IFN-β1b (which is only administered subcutaneously) where treatment began at 20 to 25% dose for 1 week, increased to 50% dose the second week, and if treatment was tolerated, increased to full dose. According to Bayas et al., interferon-β dosage should be reduced or kept at the same level for a longer time until improved drug tolerability allows an increase. Walther et al. (Walther E U, Hohlfeld R. Multiple Sclerosis Side Effects of Interferon beta Therapy and their Management. Neurology 53:1622-1627, 1999) recommended one dose reduction (between 25-50%) that should be maintained, rather than escalated, for 4-6 weeks. Thus, it was common practice to err on the side of an extended titration schedule.
- Wroe (Wroe S J. Effects of dose titration on tolerability and efficacy of interferon beta-1b in people with multiple sclerosis. J Int Med Res 33:309-18, 2005) evaluated whether a slower, four-stage, 4 week titration to a final dose of 250 μg subcutaneous IFN-β1b might improve tolerability over a more rapid two-stage, 2 week titration in patients with relapsing-remitting MS over a 3-month period. In the slow-titration group, IFN-β1b was subcutaneously administered, initially at 62.5 μg (¼ dose) every other day for 9 days, and then at ¼ dose increments (125 μg and 187.5 μg, respectively) on days 11 and 21, and a full dose (250 μg) beginning on day 31 (i.e. in the middle of week 5) for the remainder of the 3-month treatment. See FIG. 1 of Wroe et al. In the fast-titration group, IFN-β1b was subcutaneously administered, initially at 125 μg (½ dose) every other day for 2 weeks and then at full dose for the remainder of the 3-month treatment. One of the primary adverse events assessed was flu-like symptoms. Wroe reported no noticeable differences with respect to the occurrence of adverse events between the two treatment groups, e.g., the incidence rates of flu-like symptoms were similar in the slow—(32.4%) and rapid titration (41.9%) groups (FIG. 3 of Wroe et al). Wroe concluded that a rapid-titration regimen (½ dose increments, with a full dose beginning in week 3) results in a quicker onset of clinical benefit and slow titration (¼ dose increments, with a full dose beginning in the middle of week 5) showed a non-significant reduction in flu-like symptoms compared to the rapid-titration regimen.
- The Rebif® label includes titration instructions for subcutaneous administration of IFN-β1a three times per week over a 4-week period, with full dose administered in week 5:
- Weeks 1-2—⅕ of a dose-
subcutaneous injection 3×/week -
- (titration dose for 33 μg=4.4 μg)
- (titration dose for 44 μg=8.8 μg)
- Week 3-4—½ of a dose—
subcutaneous injection 3×/week -
- (titration dose for 33 μg=11 μg)
- (titration dose for 44 μg=22 μg)
-
Week 5—full dose—subcutaneous injection 3×/week - The European Rebif® label recommends a gradual increase during a 4 week period to reduce adverse reactions. The ⅕ dose during the first two weeks serves the purpose of allowing tachyphylaxis to develop, thus reducing side effects. Both the US and European labels are silent with respect to treating flu-like symptoms associated with administration of interferon-beta. All of the products and clinical studies discussed thus far relate to subcutaneous administration of IFN-β1a or IFN-β1b.
- Brandes et al. (Brandes D W, Bigley K, Hornstein W, Cohen H, Au W, Shubin R. Alleviating Flulike Symptoms with Dose Titration and Analgesics in MS Patients on Intramuscular Interferon beta-1a Therapy: a pilot study. Curr Med Research and Opinions 23(7):1667-1672, 2007), appears to be the first to investigate dose titration of intramuscular administration (IM) of IFN-β1a. Brandes et al. evaluated the effectiveness of dose titration in combination with acetaminophen or ibuprofen in reducing the flu-like side effects of Avonex® (IFN-β1a) in 47 patients with relapsing-remitting multiple sclerosis.
- The Brandes et al. study was a multi-site, randomized, open-label, 12-week study.
Group 1 patients received (IM) IFN-β1a at a dose of 30 μg once weekly with no titration.Groups weeks weeks weeks Groups mg 1 hour before each (IM) IFN-β1a injection, then every 4 hours as needed.Group 3 received ibuprofen 400mg 1 hour before each (IM) IFN-β1a injection, again at 6 hours following injection, then every 6 hours as needed. Flu-like symptoms were recorded at three time points: baseline (first dose of analgesic, 1 hour pre-injection); Time A (second dose of analgesic, 4 hours post-injection); and Time B (12-15 hours post-injection). - Brandes et al. found that one-quarter titration (
Groups 2 and 3) significantly reduced the proportion of patients with a mean increase of ≥2 from baseline in flu-like symptom score compared with no titration only at 4 hours post-injection during the first two weeks (FIG. 1A of Brandes et al., p=0.015 indicated with *). There was no significant difference between the one-quarter titration (Groups 2 and 3) and no titration (Group 1) at 4 hours during weeks 3-12 as the dose was increased. These data suggested that a ¼ dose escalation does not reduce flu-like symptoms, suggesting that further prolonged titration, i.e., an even slower titration, would be necessary. - Also, there was no significant difference between the one-quarter titration (
Groups 2 and 3) and no titration (Group 1) at 12-15 hours during any week, including the first two weeks. These data suggested that initiating (IM) IFN-β1a injection with a 1/4 dose had limited effects in reducing flu-like symptoms because the ¼ dose only delayed the onset of flu-like symptoms and only did so during the first two weeks. - Frohman et al (Frohman E et al. Disease-Modifying Therapy in Multiple Sclerosis: Strategies for Optimizing Management. Neurologist 8:227-236, 2002) in a comprehensive review of MS therapy management, recommends initiating treatment during the tapering phase of a steroid regimen and applying a fractionated dosing scheme in patients treated with either Avonex®, Rebif® or Betaseron® in combination with a nonsteroidal anti-inflammatory agent. In particular, patients were started at 25% of the recommended dose and dosages were increased by 25% increments weekly to every other week. Frohman et al. describes the 25% dose as “a dose usually associated with minimal to no side effects” given that interferon-related side effects are dose-response related. Significantly, Frohman et al. states, “If patients experience severe and limiting side effects as the dose is increased, we will generally prolong titration, escalating by the same increment every 2 to 4 weeks. With this approach, we have had very few patients fail drug initiation.” Thus, Frohman teaches to err on the side of an extended titration schedule.
- It is therefore desirable to provide a method for further reducing flu-like symptoms associated with intramuscular interferon administration, which will promote compliance and continuation of interferon therapy for MS.
- The inventors have surprisingly found that by decreasing the time period of the dose titration schedule for the intramuscular administration of interferon (“fast titration”), the appearance of flu-like symptoms is significantly reduced as compared to a longer dose titration schedule (“slow titration”).
- As such, the present invention provides a method for treating multiple sclerosis, which includes intramuscularly administering an interferon to a patient once per week, and specifically includes an initial titration period wherein the interferon is administered in an escalating dose regimen (a “titration period”). In particular, the titration period includes a one-quarter dose in week one, a one-half dose in week two, a three-quarter dose in
week 3, and a full therapeutically effective dose inweek 4 and thereafter. - The present invention also provides a method for reducing flu-like symptoms associated with the administration of an interferon to a patient with multiple sclerosis, including (a) intramuscularly administering the interferon to the patient according to an escalating dosing regimen in
weeks 1 to 3; and (b) intramuscularly administering a full therapeutically effective dose of interferon inweek 4. - The invention also relates to a titration package for enabling compliance with these methods, wherein the dosage of interferon changes over a period of time. The titration package includes interferon delivery devices containing an interferon, and instructions for the patient to administer the interferon in an escalating dose regimen during a titration period.
- The foregoing and other objects, features and advantages of the invention will be apparent from the following more particular description of preferred embodiments of the invention.
- The accompanying Figures, which are incorporated herein and form part of the specification, illustrate embodiments of the present invention and, together with the description, further serve to explain the principles of the invention.
-
FIG. 1 is a flow chart showing the design of a “fast vs. slow” titration trial. Note that in the Example below, additional subjects were investigated. -
FIG. 2 is a table with the titration schedules in a clinical study. Patients inTreatment Group 1 received a full intramuscular dose of Avonex® each week for 8 weeks. Patients inTreatment Group 2 received intramuscular doses of Avonex® according to a fast titration schedule (¼ dose inweek 1, ½ dose inweek 2, ¾ dose inweek 3, and full dose in weeks 4-8). Patients inTreatment Group 3 received intramuscular doses of Avonex® according to a slow titration schedule (¼ dose in weeks 1-2, ½ dose in weeks 3-4, ¾ dose in weeks 5-6, and full dose in weeks 7-8). All patient groups received prophylactic medication. -
FIG. 3 describes a method of scoring flu-like symptoms (FLS) in accordance with the invention. -
FIG. 4 is a line graph of the primary outcome variable and shows the change in total flu-like symptom (FLS) score from pre-injection to 4 to 6 hours after injection over 8 weeks. -
FIG. 5 is a line graph of the secondary outcomes variable and shows the change in total flu-like symptom (FLS) score from pre-injection to 12 to 15 hours after injection over 8 weeks. -
FIG. 6 is a table of the secondary outcome variable and provides the odds ratio of incidence of flu-like symptom (FLS) score at 4 to 6 hours and at 12 to 15 hours after injection over 8 weeks. -
FIG. 7 provides data comparing the effect on flu-like symptoms of no titration, fast titration and slow titration. -
FIG. 8 is a bar graph comparing the change in flu-like symptoms (FLS) at 4-6 hours, comparing no titration to fast titration. -
FIG. 9 provides data comparing the effect on flu-like symptoms of no titration to slow titration. - The invention provides a method for treating a subject with multiple sclerosis, by intramuscularly administering an interferon using an initial escalating dosage regimen or titration period. Treatment is preferably once a week. The escalating dosage regimen typically involves administration of a one-quarter dose in week one, a one-half dose in week two, a three-quarter dose in
week 3, and a full therapeutically effective dose inweek 4 and thereafter. - In a preferred embodiment, the week one dose is about 7.5 micrograms, the week two dose is about 15 micrograms, the week three dose is about 22.5 micrograms, and the week four dose is about 30 micrograms.
- In a preferred embodiment, the interferon is interferon β. In a more preferred embodiment, the interferon is an interferon β1. In a most preferred embodiment, the interferon is interferon β1a.
- The invention also provides a method for reducing the flu-like symptoms which can accompany the intramuscular administration of an interferon. In particular, the invention provides a method involving the intramuscularly administration of interferon to the patient according to an escalating dosing regimen in
weeks 1 to 3; and then the administration of a full therapeutically effective dose of interferon inweek 4. - Reducing flu-like symptoms can be measured in reduction of severity of symptoms, and/or reduction in incidence of flu-like symptoms. The reduction can be measured at various timepoints post-injection, for example 4 to 6 hours post-injection and 12 to 15 hours post-injection.
- Preferably, the reduction in severity of flu-like symptoms at 4 to 6 hours is at least 40%, more preferably at least 50%, even more preferably at least 60%, and most preferably at least 70%. The reduction in severity of flu-like symptoms at 12 to 15 hours is preferably at least 10%, more preferably at least 20%, even more preferably at least 25%, and most preferably at least 30%.
- The reduction in incidence of flu-like symptoms at 4 to 6 hours is preferably at least 5%, more preferably at least 10%, even more preferably at least 15%, and most preferably about 20%. Preferably, the reduction in incidence of flu-like symptoms at 12 to 15 hours is at least 10%, more preferably at least 15%, even more preferably at least 20%, and most preferably about 25%.
- In a preferred embodiment, the invention includes administering one quarter of the therapeutically effective dose in
week 1, half of the therapeutically effective dose inweek 2, and three-quarters of the full therapeutically effective dose inweek 3. - In a most preferred embodiment, the full therapeutically effective dose is 30 micrograms.
- Flu-like symptoms can include, for example, fever, muscle aches (myalgia), chills, sweating, fatigue, headache, and malaise, and can be scored in accordance with the method of
FIG. 3 . - The methods of the invention can further include the administration of an analgesic or anti-inflammatory drug, or a mixture thereof. The drug may be a steroid or a non-steroidal anti-inflammatory drug. Preferred drugs include acetaminophen and ibuprofen.
- The invention also provides titration packages, wherein the interferon is presented in a way to promote compliance with the escalating dosage regimen, and ultimately the long-term treatment using the interferon.
- In a preferred embodiment, the package includes interferon and delivery devices for the interferon. The interferon may be in lyophilized form, and thus packaged in a jar or vial. In this case, the package also preferably contains a device, such as a syringe, which is pre-filled with a diluent for lyophilized interferon.
- Alternatively, the interferon may in liquid form. In this case, the interferon may be provided in pre-filled syringes. The syringes may be provided with the exact dosage for weeks 1-4 and thereafter. Alternatively, an accessory to the delivery device may also be provided, which when used in combination with the syringe, is capable of titrating the correct volume or dosage for the particular week of the escalating dosage regimen (titration period).
- Where the interferon is provided in a syringe, the syringe may also be provided with a needle stick prevention device. Such a prevention device can include a needle shield, which may be automated. The shield may be completely automatic (i.e., without any action by the patient), or may be activated by the patient.
- The interferon may also be provided in other delivery devices, such as a pen.
- The titration package also preferably contains instructions for intramuscular administration of the interferon by a patient during a titration period, wherein the interferon is preferably administered at a one-quarter dose in week one, a one-half dose in week two, a three-quarter dose in
week 3, and a full therapeutically effective dose inweek 4. - The following terms are used herein:
- Interferon—An “interferon” (also referred to as “IFN”) is a small, species-specific, single chain polypeptide, produced by mammalian cells in response to exposure to a variety of inducers such as viruses, polypeptides, mitogens and the like. The most preferred interferon used in the invention is glycosylated, human, interferon-β that is glycosylated at residue 80 (Asn 80) and that is preferably derived via recombinant DNA technologies. This preferred glycosylated interferon-β is called “interferon-β1a”. The term “interferon-β1a” is also intended to encompass all mutant forms (i.e., Example 1) provided that the mutants are also glycosylated at the Asn 80 residue.
- Recombinant DNA methods for producing proteins are known.
- Preferred interferon-β1a polynucleotides that may be used in the present methods of the invention are derived from the wild-type interferon β gene sequences of various vertebrates, preferably mammals and are obtained using methods that are well-known to those having ordinary skill in the art such as the methods described in the following U.S. patents: U.S. Pat. No. 5,641,656 (issued Jun. 24, 1997: DNA encoding avian type I interferon proprotein and mature avian type I interferon), U.S. Pat. No. 5,605,688 (Feb. 25, 1997-recombinant dog and horse type I interferons); U.S. Pat. No. 5,231,176 (Jul. 27, 1993, DNA molecule encoding a human leukocyte interferon)); U.S. Pat. No. 5,071,761 (Dec. 10, 1991, DNA sequence coding for sub-sequences of human lymphoblastoid interferons LyIFN-alpha-2 and LyIFN-alpha-3); U.S. Pat. No. 4,970,161 (Nov. 13, 1990, DNA sequence coding for human interferon-gamma); U.S. Pat. No. 4,738,931 (Apr. 19, 1988, DNA containing a human interferon beta gene); U.S. Pat. No. 4,695,543 (Sep. 22, 1987, human alpha-interferon Gx-1 gene and U.S. Pat. No. 4,456,748 (Jun. 26, 1984, DNA encoding sub-sequences of different, naturally, occurring leukocyte interferons).
- Mutants of interferon-β1a may be used in accordance with this invention. Mutations are developed using conventional methods of directed mutagenesis, known to those of ordinary skill in the art. Moreover, the invention provides for functionally equivalent interferon-β1a polynucleotides that encode for functionally equivalent interferon-beta-1a polypeptides.
- In summary, the term “interferon” includes, but is not limited to, the agents listed above as well as their functional equivalents. As used herein, the term “functional equivalent” therefore refers to an interferon-β1a protein or a polynucleotide encoding the interferon-beta-1a protein that has the same or an improved beneficial effect on the mammalian recipient as the interferon of which it is deemed a functional equivalent. As will be appreciated by one of ordinary skill in the art, a functionally equivalent protein can be produced by recombinant techniques, e.g., by expressing a “functionally equivalent DNA”. Accordingly, the instant invention embraces interferon-β1a proteins encoded by naturally-occurring DNAs, as well as by non-naturally-occurring DNAs which encode the same protein as encoded by the naturally-occurring DNA. Due to the degeneracy of the nucleotide coding sequences, other polynucleotides may be used to encode interferon-β1a. These include all, or portions of the above sequences which are altered by the substitution of different codons that encode the same amino acid residue within the sequence, thus producing a silent change. Such altered sequences are regarded as equivalents of these sequences. For example, Phe (F) is coded for by two codons, TTC or TTT, Tyr (Y) is coded for by TAC or TAT and His (H) is coded for by CAC or CAT. On the other hand, Trp (W) is coded for by a single codon, TGG. Accordingly, it will be appreciated that for a given DNA sequence encoding a particular interferon there will be many DNA degenerate sequences that will code for it.
- The interferon may be administered per se as well as in the form of pharmaceutically acceptable esters, salts, and other physiologically functional derivatives thereof. In such pharmaceutical and medicament formulations, the interferon preferably is utilized together with one or more pharmaceutically acceptable carrier(s) and optionally any other therapeutic ingredients. The carrier(s) must be pharmaceutically acceptable in the sense of being compatible with the other ingredients of the formulation and not unduly deleterious to the recipient thereof. The interferon is provided in an amount effective to achieve the desired pharmacological effect, as described above, and in a quantity appropriate to achieve the desired daily dose.
- The formulations include those suitable for intramuscular administration.
- The formulations may conveniently be presented in unit dosage forms and may be prepared by any of the methods well known in the art of pharmacy. Such methods generally include the step of bringing the active ingredient(s) into association with a carrier which constitutes one or more accessory ingredients. Typically, the formulations are prepared by uniformly and intimately bringing the active ingredient(s) into association with a liquid carrier.
- The formulations may be presented in unit-dose or multi-dose form.
- In addition to the aforementioned ingredients, the formulations may further include one or more accessory ingredient(s) selected from diluents, buffers, disintegrants, surface active agents, thickeners, lubricants, preservatives (including antioxidants), and the like.
- In yet more detail, the present invention is described by the following items which represent additional embodiments hereof.
- 1. A method for treating multiple sclerosis, including intramuscularly administering an interferon to a patient once per week, wherein treatment begins with a titration period wherein the interferon is administered at a one-quarter dose in week one, a one-half dose in week two, a three-quarter dose in
week 3, and a full therapeutically effective dose inweek 4 and thereafter. - 2. The method of
item 1, wherein the week one dose is about 7.5 micrograms, the week two dose is about 15 micrograms, the week three dose is about 22.5 micrograms, and the week four dose is about 30 micrograms. - 3. The method of
item 1, wherein the interferon is interferon β1a. - 4. A method for reducing flu-like symptoms associated with administration of an interferon to a patient with multiple sclerosis, including:
- (a) intramuscularly administering the interferon to the patient according to an escalating dosing regimen in
weeks 1 to 3; and - (b) intramuscularly administering a full therapeutically effective dose of interferon in
week 4. - 5. The method of
item 4, wherein the escalating dosing regimen comprises administering one quarter of the therapeutically effective dose inweek 1, half of the therapeutically effective dose inweek 2, and three-quarters of the therapeutically effective dose inweek 3. - 6. The method of
item 4, wherein the interferon is interferon β1a. - 7. The method of
item 4, wherein the full therapeutically effective dose is 30 micrograms. - 8. The method of
item 4, wherein the flu-like symptoms include fever, muscle aches, chills, sweating, fatigue, headache, and malaise. - 9. A titration package for enabling compliance with a regimen of changing dosage of an interferon over a period of time, the package including interferon delivery devices containing an interferon and instructions for administration by a patient during a titration period, wherein the interferon is administered at a one-quarter dose in week one, a one-half dose in week two, a three-quarter dose in
week 3, and a full therapeutically effective dose inweek 4. - 10. The titration package of item 9, wherein the instructions indicate a week one dosage of about 7.5 micrograms, a week two dose of about 15 micrograms, a week three dosage of about 22.5 micrograms, and a week four dosage of about 30 micrograms.
- 11. The titration package of item 9, wherein the interferon is provided in a vial in lyophilized form.
- 12. The titration package of item 11, further comprising a vial adapter and a syringe pre-filled with a diluent for said lyophilized interferon.
- 13. The titration package of item 9, wherein the interferon is provided in a liquid formulation.
- 14. The titration package of item 13, wherein the liquid interferon formulation is provided in pre-filled syringes.
- 15. The titration package of item 14, wherein the pre-filled syringes are filled with a correct dosage for weeks one to four.
- 16. The titration package of item 9, wherein the delivery device comprises an auto-injector.
- 17. The titration package of item 9, wherein the delivery device is needle-free.
- 18. The titration package of item 9, wherein the deliver device is a pen.
- 19. The titration package of item 9, further comprising a needle stick prevention device.
- 20. The titration package of item 19, wherein the needle-stick prevention device includes a needle shield.
- 21. The titration package of item 20, wherein the shield is activated manually by the patient.
- 22. The titration package of item 20, wherein the shield is automated.
- 23. The titration package of item 22, wherein the automated shield is activated by the patient.
- 24. The titration package of item 22, wherein the needle is automatically shielded without any action by the patient.
- 25. The titration package of item 22, wherein the needle is shielded without any action by the patient.
- 26. The titration package of item 9, wherein the package further includes a dose-limiting titration device.
- 27. The method of any of items 1-8, further comprising administration of an analgesic or anti-inflammatory drug, or a mixture thereof.
- 28. The method of item 27, wherein the drug is a steroid.
- 29. The method of item 27, wherein the drug is a non-steroidal anti-inflammatory agent.
- 30. The method of item 27, wherein the drug is acetaminophen.
- 31. The method of item 27, wherein the drug is ibuprofen.
- The compositions and processes of the present invention will be better understood in connection with the following examples, which are intended as an illustration only and not limiting of the scope of the invention. Various changes and modifications to the disclosed embodiments will be apparent to those skilled in the art and such changes and modifications including, without limitation, those relating to the processes, formulations and/or methods of the invention may be made without departing from the spirit of the invention and the scope of the appended claims.
- Avonex® was studied in a randomized, three-arm, dose-blinded, parallel-group study to determine the effect of Avonex® dose titration, administered intramuscularly, on the severity and incidence of IFN-β1a-related flu-like symptoms in healthy volunteers. The approved therapeutic dose of Avonex® is 30 μg weekly by IM administration.
- In this blinded, parallel-group study, subjects were randomized to 1 of 3 treatment arms:
Group 1—no titration (weekly IM IFN-β 1a 30 μg for 8 weeks);Group 2—fast dose titration (quarter-dose increments every week up to 30 μg over 3 weeks, full dose to Week 8); andGroup 3—slow dose titration (quarter-dose increments every 2 weeks up to 30 μg over 6 weeks, full dose to Week 8). SeeFIG. 1 . In order to evaluate flu-like symptoms (FLS) in a controlled condition and to avoid bias, all subjects, regardless of symptoms, were administered prophylactic medication (acetaminophen 650 milligrams (mg) orally within 1 hour prior to Avonex® injection, and at 4 to 6 hours, 8 to 10 hours, and 12 to 15 hours following injection.) - Each week, the presence and intensity of fever, muscle aches (myalgia), chills, and fatigue symptoms were recorded at pre-injection, 4 to 6 hours and 12 to 15 hours post injection. Each FLS was assigned a score from 0 to 3 by the investigator as follows: 0=absent; 1=mild, did not interfere with daily activities; 2=moderate, sufficient to interfere with daily activities; 3=severe, bed rest required. Body temperature was recorded to determine the presence of fever using the following scale: 0 (<99.1° F.); 1 (≥99.1° F. but <100.1° F.); 2 (≥100.1° F. but <101.1° F.); 3 (≥101.1° F.). The total score (sum of the 3 symptom scores and fever score) for each of the 3 timepoints (pre-injection, 4 to 6 hours, and 12 to 15 hours) was be calculated during data analysis. For each timepoint, the maximum total score was 12 and the minimum total score was 0. A total score of 2 points or greater above the pre-injection score was considered positive for the presence of FLS.
- A total of 234 subjects were enrolled, 78 per arm, and 195 (83%) completed the study. The majority of subjects were female (62%) and the mean age was 32.9 years. Subjects in the fast and slow titration arms had significantly less severe FLS over 8 weeks than subjects in full-dose arm at 4-6 hours post injection (0.132 [P<0.001] and 0.267 [P<0.001] vs 0.539) (see
FIG. 2 ) and 12 to 15 hours post injection (0.475 [P<0.001] and 0.515 [P=0.002] vs 0.753) (seeFIG. 3 ). When compared to the no titration group at 4-6 hours post injection, the incidence of FLS was significantly less for the fast titration group (odds ratio [OR]: 0.179 [0.075, 0.429], P<0.001) and the slow titration group (OR: 0.414 [0.194, 0.994], P=0.023) (seeFIG. 4 ). Similar results were demonstrated at 12-15 hours post injection (fast titration OR: 0.469 [0.272, 0.907], P=0.006; slow titration OR: 0.562 [0.338, 0.936], P=0.027) (seeFIG. 4 ). - The patent and scientific literature referred to herein establishes the knowledge that is available to those with skill in the art. All United States patents and published or unpublished United States patent applications cited herein are incorporated by reference. All published foreign patents and patent applications cited herein are hereby incorporated by reference. All other published references, documents, manuscripts and scientific literature cited herein are hereby incorporated by reference.
- While this invention has been particularly shown and described with references to preferred embodiments thereof, it will be understood by those skilled in the art that various changes in form and details may be made therein without departing from the scope of the invention encompassed by the appended claims.
Claims (13)
1. A combination of delivery devices and dose-limiting accessory devices for use in reducing the severity of flu-like symptoms associated with treating a patient having multiple sclerosis with intramuscularly administered interferon-β-1a over an eight week period,
wherein the combination comprises interferon-β-1a, delivery devices and dose-limiting accessory devices for once a week intramuscular administration to a patient having multiple sclerosis according to a first schedule comprising:
a first delivery device for intramuscular administration of interferon-β-1a to the patient and a first dose-limiting accessory configured to limit dispensing of the first titration dose from the first delivery device to 7.5 μg of the interferon-β-1a in week one;
a second delivery device for intramuscular administration of interferon-β-1a to the patient and a second dose-limiting accessory configured to limit dispensing of the second titration dose from the second delivery device to 15 μg of the interferon-β-1a in week two;
a third delivery device for intramuscular administration of interferon-β-1a to the patient and a third dose-limiting accessory configured to limit dispensing of the third titration dose from the third delivery device to 22.5 μg of the interferon-β-1a in week three; and
a fourth delivery device for intramuscular administration of 30 μg interferon-β-1a to the patient;
wherein the combination reduces severity of the flu-like symptoms at 4-6 hours and at 12-15 hours after each intramuscular administration of interferon-β-1a throughout an eight week period which includes once a week intramuscular administration of 30 μg of interferon-β-1a to the patient in weeks four through eight
(i) when compared to the severity of the flu-like symptoms at 4-6 hours and at 12-15 hours after each intramuscular administration of interferon-β-1a in a second schedule comprising once a week intramuscular administration of 30 μg of interferon-β-1a to a patient having multiple sclerosis for eight weeks; and
(ii) when compared to the severity of the flu-like symptoms at 4-6 hours and at 12-15 hours after each intramuscular administration of interferon-β-1a in a once a week intramuscular administration of the medicament to a patient having multiple sclerosis according to a third schedule comprising:
intramuscular administration of 7.5 μg of interferon-β-1a to the patient in weeks one and two;
intramuscular administration of 15 μg of interferon-β-1a to the patient in weeks three and four;
intramuscular administration of 22.5 μg of interferon-β-1a to the patient in weeks five and six; and
intramuscular administration of 30 μg of interferon-β-1a to the patient in weeks seven and eight.
2. The combination of claim 1 , further comprising vials containing the interferon-β-1a in lyophilized form.
3. The combination of claim 2 , further comprising a vial adapter and the delivery devices are syringes pre-filled with a diluent for said lyophilized interferon-β-1a.
4. The combination of claim 1 , wherein the delivery devices are pre-filled syringes containing interferon-β-1a in liquid form.
5. The combination of claim 1 , wherein the delivery device comprises an auto-injector.
6. The combination of claim 1 , wherein the delivery device is needle-free.
7. The combination of claim 1 , wherein the delivery device is a pen.
8. The combination of claim 1 , further comprising a needle stick prevention device.
9. The combination of claim 1 , wherein the needle-stick prevention device comprises a needle shield.
10. The combination of claim 9 , wherein the shield is configured to be activated manually by a user.
11. The combination of claim 9 , wherein the shield is automated.
12. The combination of claim 11 , wherein the automated shield is configured to be activated by a user.
13. The combination of claim 11 , wherein the needle is configured to be automatically shielded without any action by the user.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US17/827,282 US20220280610A1 (en) | 2011-03-15 | 2022-05-27 | Method for reducing flu-like symptoms associated with intramuscular administration of interferon using a fast titration escalating dosing regimen |
Applications Claiming Priority (7)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201161452807P | 2011-03-15 | 2011-03-15 | |
US201161476930P | 2011-04-19 | 2011-04-19 | |
US13/421,197 US9198955B2 (en) | 2011-03-15 | 2012-03-15 | Method for reducing flu-like symptoms associated with intramuscular administration of interferon using a fast titration escalating dosing regimen |
US14/936,228 US20160101157A1 (en) | 2011-03-15 | 2015-11-09 | Method for reducing flu-like symptoms associated with intramuscular administration of interferon using a fast titration escalating dosing regimen |
US15/695,587 US10500254B2 (en) | 2011-03-15 | 2017-09-05 | Method for reducing flu-like symptoms associated with intramuscular administration of interferon using a fast titration escalating dosing regimen |
US16/660,038 US20200046804A1 (en) | 2011-03-15 | 2019-10-22 | Method for reducing flu-like symptoms associated with intramuscular administration of interferon using a fast titration escalating dosing regimen |
US17/827,282 US20220280610A1 (en) | 2011-03-15 | 2022-05-27 | Method for reducing flu-like symptoms associated with intramuscular administration of interferon using a fast titration escalating dosing regimen |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US16/660,038 Continuation US20200046804A1 (en) | 2011-03-15 | 2019-10-22 | Method for reducing flu-like symptoms associated with intramuscular administration of interferon using a fast titration escalating dosing regimen |
Publications (1)
Publication Number | Publication Date |
---|---|
US20220280610A1 true US20220280610A1 (en) | 2022-09-08 |
Family
ID=46045072
Family Applications (5)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US13/421,197 Active US9198955B2 (en) | 2011-03-15 | 2012-03-15 | Method for reducing flu-like symptoms associated with intramuscular administration of interferon using a fast titration escalating dosing regimen |
US14/936,228 Abandoned US20160101157A1 (en) | 2011-03-15 | 2015-11-09 | Method for reducing flu-like symptoms associated with intramuscular administration of interferon using a fast titration escalating dosing regimen |
US15/695,587 Active US10500254B2 (en) | 2011-03-15 | 2017-09-05 | Method for reducing flu-like symptoms associated with intramuscular administration of interferon using a fast titration escalating dosing regimen |
US16/660,038 Abandoned US20200046804A1 (en) | 2011-03-15 | 2019-10-22 | Method for reducing flu-like symptoms associated with intramuscular administration of interferon using a fast titration escalating dosing regimen |
US17/827,282 Pending US20220280610A1 (en) | 2011-03-15 | 2022-05-27 | Method for reducing flu-like symptoms associated with intramuscular administration of interferon using a fast titration escalating dosing regimen |
Family Applications Before (4)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US13/421,197 Active US9198955B2 (en) | 2011-03-15 | 2012-03-15 | Method for reducing flu-like symptoms associated with intramuscular administration of interferon using a fast titration escalating dosing regimen |
US14/936,228 Abandoned US20160101157A1 (en) | 2011-03-15 | 2015-11-09 | Method for reducing flu-like symptoms associated with intramuscular administration of interferon using a fast titration escalating dosing regimen |
US15/695,587 Active US10500254B2 (en) | 2011-03-15 | 2017-09-05 | Method for reducing flu-like symptoms associated with intramuscular administration of interferon using a fast titration escalating dosing regimen |
US16/660,038 Abandoned US20200046804A1 (en) | 2011-03-15 | 2019-10-22 | Method for reducing flu-like symptoms associated with intramuscular administration of interferon using a fast titration escalating dosing regimen |
Country Status (24)
Country | Link |
---|---|
US (5) | US9198955B2 (en) |
EP (1) | EP2686002B1 (en) |
JP (2) | JP6279905B2 (en) |
KR (1) | KR102050339B1 (en) |
CN (1) | CN103702680A (en) |
AU (1) | AU2012229104B2 (en) |
BR (1) | BR112013023609A8 (en) |
CA (1) | CA2846786C (en) |
CY (1) | CY1120176T1 (en) |
DK (1) | DK2686002T3 (en) |
EA (1) | EA028448B1 (en) |
ES (1) | ES2666850T3 (en) |
HR (1) | HRP20180621T1 (en) |
HU (1) | HUE036931T2 (en) |
IL (1) | IL228425A (en) |
LT (1) | LT2686002T (en) |
MX (1) | MX359947B (en) |
PL (1) | PL2686002T3 (en) |
PT (1) | PT2686002T (en) |
RS (1) | RS57175B1 (en) |
SG (1) | SG193446A1 (en) |
SI (1) | SI2686002T1 (en) |
WO (1) | WO2012125809A1 (en) |
ZA (1) | ZA201306933B (en) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9198955B2 (en) * | 2011-03-15 | 2015-12-01 | Biogen Inc. | Method for reducing flu-like symptoms associated with intramuscular administration of interferon using a fast titration escalating dosing regimen |
US10106775B2 (en) | 2014-01-09 | 2018-10-23 | Kyushu University, National University Corporation | Method of producing microglial cells |
WO2018056584A1 (en) | 2016-09-21 | 2018-03-29 | 삼성전자 주식회사 | Method for measuring skin condition and electronic device therefor |
Family Cites Families (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4456748A (en) | 1981-02-23 | 1984-06-26 | Genentech, Inc. | Hybrid human leukocyte interferons |
EP0070906B1 (en) | 1981-02-04 | 1986-10-15 | Juridical Foundation Japanese Foundation For Cancer Research | Human interferon-beta gene |
US4695543A (en) | 1982-03-23 | 1987-09-22 | Bristol-Myers Company | Alpha Interferon GX-1 |
CA1302320C (en) | 1984-06-11 | 1992-06-02 | Hideo Niwa | Expression of human cromosomal interferon-_ in animal cells |
US5231176A (en) | 1984-08-27 | 1993-07-27 | Genentech, Inc. | Distinct family DNA encoding of human leukocyte interferons |
FI90990C (en) | 1984-12-18 | 1994-04-25 | Boehringer Ingelheim Int | Recombinant DNA molecule, transformed host organism, and method for producing interferon |
DE3685996T2 (en) | 1985-06-11 | 1993-01-14 | Ciba Geigy Ag | HYBRID INTERFERONE. |
US5641656A (en) | 1993-10-22 | 1997-06-24 | University Of Connecticut | Nucleic acids encoding avian interferon (IFN) proteins and recombinant methods using them |
CN1222315C (en) * | 1996-12-24 | 2005-10-12 | 拜奥根有限公司 | Stable liquid interferon formulations |
JP2001104482A (en) * | 1999-10-07 | 2001-04-17 | Terumo Corp | Double chamber type prefilled syringe |
JP4644185B2 (en) * | 2003-01-30 | 2011-03-02 | ベクトン・ディキンソン・アンド・カンパニー | Retainer with safety shield for drug delivery device |
MXPA06014078A (en) * | 2004-06-01 | 2007-02-15 | Ares Trading Sa | Stabilized interferon liquid formulations. |
EP1923085A1 (en) * | 2006-11-17 | 2008-05-21 | Sanofi-Aventis Deutschland GmbH | Dosing and drive mechanism for drug delivery device |
EP2486916B1 (en) * | 2006-12-18 | 2015-04-01 | Ajinomoto Althea, Inc. | Human growth hormone formulations |
JP5549048B2 (en) * | 2007-08-16 | 2014-07-16 | 味の素株式会社 | Connection structure between drug vial and prefilled syringe |
KR20120027031A (en) * | 2009-06-18 | 2012-03-20 | 와이어쓰 엘엘씨 | Lyophilized formulations for small modular immunopharmaceuticals |
US9198955B2 (en) * | 2011-03-15 | 2015-12-01 | Biogen Inc. | Method for reducing flu-like symptoms associated with intramuscular administration of interferon using a fast titration escalating dosing regimen |
-
2012
- 2012-03-15 US US13/421,197 patent/US9198955B2/en active Active
- 2012-03-15 JP JP2013558168A patent/JP6279905B2/en active Active
- 2012-03-15 PL PL12719487T patent/PL2686002T3/en unknown
- 2012-03-15 KR KR1020137027053A patent/KR102050339B1/en active IP Right Grant
- 2012-03-15 LT LTEP12719487.6T patent/LT2686002T/en unknown
- 2012-03-15 HU HUE12719487A patent/HUE036931T2/en unknown
- 2012-03-15 RS RS20180455A patent/RS57175B1/en unknown
- 2012-03-15 CA CA2846786A patent/CA2846786C/en active Active
- 2012-03-15 DK DK12719487.6T patent/DK2686002T3/en active
- 2012-03-15 SI SI201231281T patent/SI2686002T1/en unknown
- 2012-03-15 WO PCT/US2012/029201 patent/WO2012125809A1/en active Application Filing
- 2012-03-15 PT PT127194876T patent/PT2686002T/en unknown
- 2012-03-15 AU AU2012229104A patent/AU2012229104B2/en active Active
- 2012-03-15 MX MX2013010507A patent/MX359947B/en active IP Right Grant
- 2012-03-15 SG SG2013069018A patent/SG193446A1/en unknown
- 2012-03-15 BR BR112013023609A patent/BR112013023609A8/en not_active Application Discontinuation
- 2012-03-15 EA EA201301024A patent/EA028448B1/en unknown
- 2012-03-15 CN CN201280019863.2A patent/CN103702680A/en active Pending
- 2012-03-15 ES ES12719487.6T patent/ES2666850T3/en active Active
- 2012-03-15 EP EP12719487.6A patent/EP2686002B1/en active Active
-
2013
- 2013-09-12 IL IL228425A patent/IL228425A/en active IP Right Grant
- 2013-09-12 ZA ZA2013/06933A patent/ZA201306933B/en unknown
-
2015
- 2015-11-09 US US14/936,228 patent/US20160101157A1/en not_active Abandoned
-
2017
- 2017-09-05 US US15/695,587 patent/US10500254B2/en active Active
- 2017-09-05 JP JP2017170640A patent/JP6522069B2/en active Active
-
2018
- 2018-04-18 HR HRP20180621TT patent/HRP20180621T1/en unknown
- 2018-04-23 CY CY20181100424T patent/CY1120176T1/en unknown
-
2019
- 2019-10-22 US US16/660,038 patent/US20200046804A1/en not_active Abandoned
-
2022
- 2022-05-27 US US17/827,282 patent/US20220280610A1/en active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20220280610A1 (en) | Method for reducing flu-like symptoms associated with intramuscular administration of interferon using a fast titration escalating dosing regimen | |
EP2533634B1 (en) | Neuroprotection in demyelinating diseases | |
AU776181B2 (en) | Combined treatment of multiple sclerosis | |
NZ712273B2 (en) | Method for reducing flu-like symptoms associated with intramuscular administration of interferon using a fast titration escalating dosing regimen | |
NZ616536B2 (en) | Method for reducing flu-like symptoms associated with intramuscular administration of interferon using a fast titration escalating dosing regimen | |
EP1471974B1 (en) | Tumor necrosis factor combined with interferon in demyelinating diseases | |
Johnson | Role of interferons in demyelinating disease |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
STPP | Information on status: patent application and granting procedure in general |
Free format text: DOCKETED NEW CASE - READY FOR EXAMINATION |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: NON FINAL ACTION MAILED |